Cover Image
市場調查報告書

腫瘤壞死因子受體超級家族成員5 (B細胞表面抗原CD40/CD40L受體/CD40):開發中產品分析

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 363118
出版日期 內容資訊 英文 75 Pages
訂單完成後即時交付
價格
Back to Top
腫瘤壞死因子受體超級家族成員5 (B細胞表面抗原CD40/CD40L受體/CD40):開發中產品分析 Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Pipeline Review, H2 2017
出版日期: 2017年08月08日 內容資訊: 英文 75 Pages
簡介

本報告提供全球各國的腫瘤壞死因子受體超級家族成員5 (B細胞表面抗原CD40或CD40L受體或CD40) 治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

目錄

  • 簡介
    • 分析範圍
  • 腫瘤壞死因子受體超級家族成員5 (B細胞表面抗原CD40/CD40L受體/CD40)概要
  • 治療藥的開發
    • 臨床實驗的各階段
    • 各治療領域
    • 各症狀
  • 開發中產品的概要
    • 後期階段的產品
    • 初期階段的產品
  • 各企業開發中的細菌性肺炎治療藥
  • 細菌性肺炎:治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥法
    • 各分子類型
  • 開發治療藥的企業
    • Alligator Bioscience AB
    • Apexigen, Inc.
    • Apogenix GmbH
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Celldex Therapeutics, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Kyowa Hakko Kirin
    • Novartis AG
    • Seattle Genetics, Inc.
    • Zyrnat Biotherapeutics SL
  • 藥物簡介
    • 2C-10
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的發展情形
    • ADC-1013
    • APG-1233
    • APX-005M
    • BI-655064
    • bleselumab
    • BMS-986090
    • CFZ-533
    • FFP-104
    • KGYY-15
    • 淋巴瘤CD40工作用單株抗體
    • RG-7876
    • SEA-CD40
    • 薄膜樣腎絲球腎炎CD40標的疫苗
    • ZY-11
  • 開發暫停的產品
  • 開發中止的產品
  • 值得注意的最新趨勢、新聞稿 (共11件)
  • 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0959TDB

Summary:

According to the recently published report 'Tumor Necrosis Factor Receptor Superfamily Member 5 - Pipeline Review, H2 2017'; Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) pipeline Target constitutes close to 21 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes.

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Tumor Necrosis Factor Receptor Superfamily Member 5 is a member of the TNF-receptor superfamily. This protein is a receptor on antigen-presenting cells of the immune system and is essential for mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. The interaction of this receptor and its ligand is found to be necessary for amyloid-beta-induced microglial activation, and thus is thought to be an early event in Alzheimer disease pathogenesis.

The report 'Tumor Necrosis Factor Receptor Superfamily Member 5 - Pipeline Review, H2 2017' outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 6, 4 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Gastrointestinal, Central Nervous System, Genito Urinary System And Sex Hormones, Hematological Disorders, Hormonal Disorders and Metabolic Disorders which include indications Solid Tumor, Crohn's Disease (Regional Enteritis), Kidney Transplant Rejection, Lymphoma, Melanoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Ovarian Cancer, Rheumatoid Arthritis, Adenocarcinoma Of The Gastroesophageal Junction, Bladder Cancer, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Gastroesophageal (GE) Junction Carcinomas, Graves Diseases, Heart Transplant Rejection, Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hyperthyroidism, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Lupus Nephritis, Membranous Glomerulonephritis, Metastatic Adenocarcinoma of The Pancreas, Metastatic Melanoma, Metastatic Ovarian Cancer, Multiple Sclerosis, Myasthenia Gravis, Osteosarcoma, Pancreatic Islet Transplant Rejection, Primary Biliary Cirrhosis, Prostate Cancer, Renal Cell Carcinoma, Sicca Syndrome (Sjogren), Type 1 Diabetes (Juvenile Diabetes) and Ulcerative Colitis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40)
  • The report reviews Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Overview
    • Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Apexigen Inc
    • Apogenix GmbH
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Celldex Therapeutics Inc
    • Denceptor Therapeutics Ltd
    • F. Hoffmann-La Roche Ltd
    • Johnson & Johnson
    • Kyowa Hakko Kirin Co Ltd
    • Novartis AG
    • Seattle Genetics Inc
  • Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Drug Profiles
    • 2C-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ABBV-428 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APG-1233 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APX-005M - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BI-655064 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Bispecific Monoclonal Antibody to Agonize CD40 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bleselumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-986090 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CDX-1140 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CFZ-533 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DNP-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • emactuzumab + RG-7876 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FFP-104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-7107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KGYY-15 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Agonize CD40 and FCGR2B for B-cell Lymphoma and Melanoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Target CD40 for Pancreatic Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-7876 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-7876 + vanucizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SEA-CD40 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target CD40 for Membranous Glomerulonephritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Dormant Products
  • Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Discontinued Products
  • Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Product Development Milestones
    • Featured News & Press Releases
      • Jul 17, 2017: Apexigen Announces First Patient Dosed in Phase 1b/2 Clinical Trial of APX005M in Combination with Opdivo (nivolumab) in Advanced Solid Tumors
      • May 04, 2017: Alligator Bioscience presents promising immuno-oncology data at US conference; - Strong new preclinical findings for ADC-1013
      • Apr 28, 2017: Alligator Bioscience to present new pre-clinical data for ADC-1013 at PEGS conference in Boston, May 4
      • Apr 03, 2017: Phase I Clinical Trial Completes Using Cell Line Expertise at Cobra Biologics
      • Mar 23, 2017: Alligator announces completion of first phase I study with CD40 agonistic immuno-oncology antibody ADC-1013
      • Mar 21, 2017: Phase 1/2 Clinical Trial of Apexigen's APX005M in Combination with Pembrolizumab (Keytruda) Opens for Metastatic Melanoma Patients
      • Dec 05, 2016: Celldex Presents Data on CDX-1140, a Novel CD40 Agonist Antibody for Hematologic and Solid Malignancies, at the American Society of Hematology Annual Meeting
      • Nov 14, 2016: Celldex Presents Data on New Product Candidate, CDX-1140, a Novel CD40 Agonist Antibody
      • Oct 12, 2016: Alligator Bioscience informs that dosing has started in a second clinical phase I study with the CD40 Agonistic Immuno-Oncology Antibody ADC-1013
      • Apr 22, 2016: Alligator Bioscience Recieves First Milestone Payment for ADC-1013
      • Apr 18, 2016: Seattle Genetics Highlights Data on SEA-CD40 at the American Association for Cancer Research Annual Meeting
      • Apr 13, 2016: Apexigen to Present Data on Its Novel Immuno-Oncology Program APX005M at Upcoming Cancer Conferences
      • Feb 03, 2016: Fast Forward Pharmaceuticals Initiates Phase II Pilot Studies in Primary Biliary Cirrhosis and Crohn's Disease with anti-CD40 Monoclonal Antibody
      • Nov 17, 2015: Apexigen Presents Positive Data for APX005M in Podium Presentation at Immune Checkpoint Inhibitors (ICI) Europe
      • Nov 06, 2015: Apexigen Presents Preclinical Data from Novel Immuno-Oncology Candidate APX005M at SITC 2015 Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by AbbVie Inc, H2 2017
  • Pipeline by Apexigen Inc, H2 2017
  • Pipeline by Apogenix GmbH, H2 2017
  • Pipeline by Boehringer Ingelheim GmbH, H2 2017
  • Pipeline by Bristol-Myers Squibb Company, H2 2017
  • Pipeline by Celldex Therapeutics Inc, H2 2017
  • Pipeline by Denceptor Therapeutics Ltd, H2 2017
  • Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Pipeline by Johnson & Johnson, H2 2017
  • Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017
  • Pipeline by Novartis AG, H2 2017
  • Pipeline by Seattle Genetics Inc, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top